Inappropriate ileal conservation of bile acids in cholestatic liver disease: Homeostasis gone awry

Gut

Volumn 52, Issue 9, 2003, Pages 1239-1241

  Hofmann, A F ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BILE ACID; BILE ACID CONJUGATE; CELL NUCLEUS RECEPTOR; CHENODEOXYCHOLIC ACID; CHOLESTEROL 7ALPHA MONOOXYGENASE; CHOLIC ACID; COLESTYRAMINE; DEOXYCHOLIC ACID; INHIBITOR PROTEIN; TAUROCHOLIC ACID; URSODEOXYCHOLIC ACID;

BILE ACID SYNTHESIS; CHOLESTASIS; ENTEROHEPATIC CIRCULATION; HOMEOSTASIS; HUMAN; ILEUM; INTESTINE CELL; LIVER CELL; NONHUMAN; NOTE; PRIMARY BILIARY CIRRHOSIS; SMALL INTESTINE ABSORPTION;

BILE ACIDS AND SALTS; CHOLAGOGUES AND CHOLERETICS; CHOLESTASIS; HOMEOSTASIS; HUMANS; ILEUM; URSODEOXYCHOLIC ACID;

EID: 0041885458     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.52.9.1239     Document Type: Note

References (32)

1. Hofmann AF. Bile acids: their continuing importance in liver and intestinal disease. Arch Int Med 1999;159:2647-58.
2. Russell DW. The enzymes, regulation, and genetics of bile acid synthesis. Annu Rev Biochem 2003 (in press).
3. Hofmann AF. Intestinal absorption of bile acids and biliary constituents: the intestinal component of the enterohepatic circulation and the integrated system. In: Johnson LR, Alpers DH, Christensen J, et al, eds. Physiology of the gastrointestinal tract, vol 2, 3rd edn. New York: Raven Press, 1994:1845-65.
4. Vlahcevic ZR, Pandak WM, Stravitz RT. Regulation of bile acid biosynthesis. Gastroenterol Clin North Am 1999;28:1-25.
5. Makashima J, Okamoto AY, Repa JJ, et al. Identification of a nuclear receptor for bile acids. Science 1999;284:1285-6.
6. Parks DJ, Blanchard SG, Bledsoe RK, et al. Bile acids: natural ligands for an orphan nuclear receptor. Science 1999;284:1365-8.
7. Chiang JY. Bile acid regulation of gene expression: roles of nuclear hormone receptors. Endocr Rev 2002;23:443-63.
8. Mi L-Z, Devorokiondo S, Harp JM, et al. Structural basis for bile acid binding and activation of the nuclear receptor FXR. Mol Cell 2003;11:1093-100.
9. Downes M, Verdecio MA, Roecker AJ, et al. A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR. Mol Cell 2003;11:1079-92.
10. LaRusso NF, Hoffman NE, Hofmann AF, et al. Effect of primary bile acid ingestion on bile acid metabolism and biliary lipid secretion in gallstone patients. Gastroenterology 1975;69:1301-14.
11. Lillienau J, Munoz J, Longmire-Cook SJ, et al. Negative feedback regulation of the ileal bile acid transport system in rodents. Gastroenterology 1993;104:38-46.
12. Marcus SN, Schteingart CD, Marquez ML, et al. Active absorption of conjugated bile acids in vivo: kinetic parameters and molecular specificity of the ileal transport system in the rat. Gastroenterology 1991;100:212-21.
13. Schmassmann A, Fehr HF, Locher, et al. Cholylsarcosine, a new bile acid analogue: metabolism and effect on biliary secretion in humans. Gastroenterology 1993;104:1171-81.
14. Torchia EC, Cheema SK, Agellon LB. Coordinate regulation of bile acid biosynthetic and recovery pathways. Biochem Biophys Res Commun 1996;225:128-33.
15. 75Se-homocholic acid-taurine is increased in primary biliary cirrhosis, and reverts to normal during ursodeoxycholic acid administration. Gut 2003;52:1371-5.
16. Matsamura JS, Greiner MA, Nahrwold DL, et al. Reduced ileal taurocholate absorption with total parenteral nutrition. J Surg Res 1993;54:517-22.
17. Chen F, Ma L, Dawson PA, et al. Liver receptor homologue-1 mediates species- and cell line-specific bile acid-dependent negative feedback regulation of the apical sodium-dependent bile acid transporter. J Biol Chem 2003;278:19909-16.
18. 14C] tourocholate. Gastroenterology 1988;95:164-9.
19. de Caestecker JS, Jozrowi RP, Nisbetta JA, et al. Direct assessment of the mechanism for a raised serum bile acid level in chronic liver disease. Eur J Gastroenterol Hepatol 1995;7:955-61.
20. Fellous K, Jian R, Hanniche M, et al. Measurement of ileal absorption of bile salts with the selenium 75 labeled homotaurocholic acid test. Validation and clinical significance. Gastroenterol Clin Biol 1994;18:865-72.
21. Hoffman NE, Hofmann AF. Measurement of bile acid kinetics by isotope dilution in man. Gastroenterology 1974;67:314-23.
22. Paumgartner G, Beuers U. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology 2002;36:525-31.
23. Varco RL. Intermittent external biliary drainage for the relief of pruritus in certain chronic disorders of the liver. Surgery 1947;21:43-5.
24. Huet PM, Rautureau M, Dhumeaux D, et al. The effects of biliary drainage in cholestatic hepatitis. Rev Med Chir Mal Foie 1970;45:271-8.
25. DiPadova C, Tritapepe R, Rovagnati P, et al. Double-blind placebo-controlled clinical trial of microporous cholestyramine in the treatment of intra- and extra-hepatic cholestasis: relationship between itching and serum bile acids. Methods Find Exp Clin Pharmacol 1984;6:773-6.
26. Emerick KM, Whitington PF. Partial external biliary diversion for intractable pruritus and xanthomas in Alagille syndrome. Hepatology 2002;35:1501-6.
27. Hollands CM, Rivera-Pedrogo FJ, Gonzalez-Vallina R et al. Ileal exclusion for Byler's disease: an alternative surgical approach with promising early results for pruritus. J Pediatr Surg 1998;33:220-4.
28. Stange J, Hassanein TI, Mehta R, et al. The molecular adsorbents recycling system as a liver support system based on albumin dialysis: A summary of preclinical investigations, prospective, randomized, controlled clinical trial, and clinical experience from 19 centers. Artif Organs 2002;26:103-110.
29. Berg CI. Use of colesevolem hydrochloride (Welchol™) as a novel therapeutic agent for the management of refractory pruritus in chronic liver disease. Hepatology 2001;34:541.
30. Craddock AL, Love MW, Daniel RW, et al. Expression and transport properties of the human ileal and renal sodium-dependent bile acid transporter. Am J Physiol 1998;274:G157-69.
31. Telford DE, Edwards JY, Lipson SM, et al. Inhibition of both the apical sodium-dependent bile acid transporter and HMG-CoA reductase markedly enhances the clearance of LDL apo B. J Lipid Res 2003;44:943-52.
32. Vega GL, Grundy SM. Treatment of primary moderate hypercholesterolemia with lovastatin (mevinolin) and colestipol. JAMA 1987;257:33-8.